grants_govPAR-25-337
Open
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
- Response deadline
- Jan 7, 2028 Due in 509 days
- Date posted
- Dec 31, 2024
- Source
- Open notice
Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.
Classifications
- NAICS93.394
Documents (1)
- DownloadPAR-25-337-Full-Announcement.htmltext/html422 B
Contacts
- grantsinfo@nih.gov301-402-2541
Similar contracts
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)Due Nov 10, 2026
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)Due Nov 10, 2026
- Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)Due Jan 7, 2028
- Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)Due Jan 7, 2028
- Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)Due Jan 7, 2028
- Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)Due Oct 14, 2026